Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer121Funding/support: This research was supported and funded through the Center for Prostate Disease Research (CPDR), the Uniformed Services University of the Health Sciences, the Intramural Research Program of the Clinical Research Center, and the National Cancer Institute, National Institutes of Health, Bethesda, MD, US.2Presentations: These data were presented at the 2012 Annual Meeting of the American Urological Association in Atlanta, GA.-Reference-Cited by-同舟云学术

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer121Funding/support: This research was supported and funded through the Center for Prostate Disease Research (CPDR), the Uniformed Services University of the Health Sciences, the Intramural Research Program of the Clinical Research Center, and the National Cancer Institute, National Institutes of Health, Bethesda, MD, US.2Presentations: These data were presented at the 2012 Annual Meeting of the American Urological Association in Atlanta, GA.

Published:2014-08 Issue:6 Volume:32 Page:761-768
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Metwalli Adam R.,Rosner Inger L.,Cullen Jennifer,Chen Yongmei,Brand Timothy,Brassell Stephen A.,Lesperance James,Porter Christopher,Sterbis Joseph,McLeod David G.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference21 articles.

1. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy;Sonpavde;Urol Oncol,2010

2. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer;Cook;Clin Cancer Res,2006

3. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid;Jung;Eur Urol,2011

4. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression;Lein;Eur Urol,2007

5. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial;Smith;Lancet,2012

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy;Cancers;2024-07-26

2. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2023-10-11

3. Current status ofN-,O-,S-heterocycles as potential alkaline phosphatase inhibitors: a medicinal chemistry overview;RSC Advances;2023

4. Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends;Clinical Drug Investigation;2022-07-13

5. Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer;Prostate Cancer and Prostatic Diseases;2022-07-05